Hughes Simon, Yoshimoto Maisa, Beheshti Ben, Houlston Richard S, Squire Jeremy A, Evans Andrew
Applied Molecular Oncology, Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Ontario M5G 2M9, Canada.
BMC Genomics. 2006 Mar 30;7:65. doi: 10.1186/1471-2164-7-65.
Prostate cancer (CaP) is a disease with multifactorial etiology that includes both genetic and environmental components. The knowledge of the genetic basis of CaP has increased over the past years, mainly in the pathways that underlie tumourigenesis, progression and drug resistance. The vast majority of cases of CaP are adenocarcinomas that likely develop through a pre-malignant lesion and high-grade prostatic intraepithelial neoplasia (HPIN). Histologically, CaP is a heterogeneous disease consisting of multiple, discrete foci of invasive carcinoma and HPIN that are commonly interspersed with benign glands and stroma. This admixture with benign tissue can complicate genomic analyses in CaP. Specifically, when DNA is bulk-extracted the genetic information obtained represents an average for all of the cells within the sample.
To minimize this problem, we obtained DNA from individual foci of HPIN and CaP by laser capture microdissection (LCM). The small quantities of DNA thus obtained were then amplified by means of multiple-displacement amplification (MDA), for use in genomic DNA array comparative genomic hybridisation (gaCGH). Recurrent chromosome copy number abnormalities (CNAs) were observed in both HPIN and CaP. In HPIN, chromosomal imbalances involving chromosome 8 where common, whilst in CaP additional chromosomal changes involving chromosomes 6, 10, 13 and 16 where also frequently observed.
An overall increase in chromosomal changes was seen in CaP compared to HPIN, suggesting a universal breakdown in chromosomal stability. The accumulation of CNAs, which occurs during this process is non-random and may indicate chromosomal regions important in tumourigenesis. It is therefore likely that the alterations in copy number are part of a programmed cycle of events that promote tumour development, progression and survival. The combination of LCM, MDA and gaCGH is ideally suited for the identification of CNAs from small cell clusters and may assist in the discovery of potential genomic markers for early diagnosis, or identify the location of tumour suppressor genes (TSG) or oncogenes previously unreported in HPIN and CaP.
前列腺癌(CaP)是一种病因多因素的疾病,包括遗传和环境因素。过去几年中,人们对CaP遗传基础的认识有所增加,主要集中在肿瘤发生、进展和耐药性的潜在途径方面。绝大多数CaP病例为腺癌,可能通过癌前病变和高级别前列腺上皮内瘤变(HPIN)发展而来。从组织学上看,CaP是一种异质性疾病,由多个离散的浸润性癌灶和HPIN组成,这些病灶通常与良性腺体和基质相互穿插。与良性组织的这种混合会使CaP的基因组分析变得复杂。具体而言,当进行DNA批量提取时,所获得的遗传信息代表了样本中所有细胞的平均值。
为了尽量减少这个问题,我们通过激光捕获显微切割(LCM)从HPIN和CaP的单个病灶中获取DNA。然后通过多重置换扩增(MDA)对由此获得的少量DNA进行扩增,用于基因组DNA阵列比较基因组杂交(gaCGH)。在HPIN和CaP中均观察到反复出现的染色体拷贝数异常(CNA)。在HPIN中,涉及8号染色体的染色体失衡很常见,而在CaP中,还经常观察到涉及6号、10号、13号和16号染色体的其他染色体变化。
与HPIN相比,CaP中染色体变化总体增加,表明染色体稳定性普遍破坏。在此过程中发生的CNA积累是非随机的,可能表明在肿瘤发生中重要的染色体区域。因此,拷贝数的改变很可能是促进肿瘤发展、进展和存活的一系列程序性事件的一部分。LCM、MDA和gaCGH的组合非常适合从小细胞簇中鉴定CNA,并可能有助于发现早期诊断的潜在基因组标记,或确定HPIN和CaP中先前未报道的肿瘤抑制基因(TSG)或癌基因的位置。